 As referred at post 333
Report per website: ""The accurate, consistent, and scalable estimation of cerebellar atrophy would be highly beneficial for clinical trials in multiple system atrophy (MSA)1-3. This work performs validation of a fully automatic volume change
workflow in MSA using Jacobian integration from non-linear warp-fields estimated with a convolutional neural
network (CNN)-based 3D T1- weighted (T1W) image analysis workflow.
The developed framework provides a fully automatic solution for estimating cerebellar volume change with increased sensitivity over comparable methods. Additionally, the framework is flexible and highly scalable, and
as such has the potential to be advantageous for future clinical trials"
My prompt for GPT3.5: What does [it] mean?
GPT output:
"This paragraph describes a study aimed at developing and validating a computer-based method for accurately and consistently estimating changes in the size of the cerebellum, a part of the brain, in patients with a neurodegenerative disorder called multiple system atrophy (MSA). The researchers used a convolutional neural network (CNN)-based 3D T1-weighted (T1W) image analysis workflow to estimate cerebellar volume changes over time in MSA patients. They found that this approach was fully automatic and more sensitive than comparable methods. The researchers suggest that this framework has the potential to be beneficial for future clinical trials of MSA treatment."
I can understand/appreciate that - but don't know if GPT is correct. If it is, I suggest the company use it to help non-scientists.
GPT doesn't refer to "Jacobian integration" in its re-write so I asked it what it was, (assuming I was a year 13 student).
It answered:
"Jacobian integration is a mathematical technique that is used to measure the changes in the shape and size of an object over time. Specifically, it calculates how much a certain point in an object has moved from its original position to its new position, as well as how much the surrounding areas of that point have changed.
To help you visualize this, imagine a rubber ball that is being squished and stretched in different directions. If you were to pick a point on the surface of the ball and track how it moves as the ball changes shape, that's essentially what Jacobian integration does. It measures the amount of deformation or stretching that occurs at that point and calculates how much the point has moved in the process. This technique can be used in a variety of applications, such as analysing changes in the brain over time, or tracking the movement of fluids in a system."
Now THAT explanation with an analogy is clever and useful.
I am posting this because I believe that understanding at least an outline of the company's progress and skillsets is "on topic" for investors.
I hope you agree. |
Given the CEO's history of involvement in M&A and other references in the directors' biogs it would seem the company strategy may be directed towards a trade sale.
The cons at the moment include stalling sales levels, net annual losses and that it is still "tiny". The value of the R&D may surprise us - particularly whilst this current bout of "AI fever" persists. It would be disappointing if it was sold at or below the current low share valuation.
I wonder where @halfpenny has sourced his "huge increasing interest of its AI Products" which is repeated by him regularly:)
Anyway - I noticed (from IXI website) that they presented a scientific paper recently in Sweden. I didn't understand the report and got it translated by GPT3.5 (though I don't know if its much clearer re-write is in fact, correct).
I'll post the original, the prompt I used, and the revised version below.
I don't hold at the moment but interested.
DYOR |
RNS yesterday gone unnoticed! |
Another Order for IXI so expect plenty more in the pipeline. Takeover target at these levels so needs rapid orders. Interesting times ahead so got more at these levels.
IXI have a huge increasing interest of its AI Products , is this when the company orders and sales pipeline grows quickly.
Maybe a Takeover still on the cards as IXICO price levels are attractive at the current levels.
IXI future is very bright so get ready for dramatic price increases ahead.
Following yesterday RNS Expect further RNS soon on great Deals. |
Looks to have bottomed..on the turn now. |
Pretty decent sized off book sell to MM @ 445,000 shares at @ 22.675p put through yesterday morning. |
IXI have a huge increasing interest of its AI Products , is this when the company orders and sales pipeline grows quickly.
Maybe a Takeover still on the cards as IXICO price levels are attractive at the current levels.
IXI future is very bright so get ready for dramatic price increases ahead.
Expect further RNS soon on great Deals. |
@Janedeer.
You make a good point about still not seeing the breakthrough in AD work. As you highlight this is not an AD contract but in the long run is a possible stepping stone towards one as it at least puts them in the right pond. As I am sure you know there are over 400 different types of dementia,I am still trying to identify who the client for this recent win is. Have you been able to figure it out ?
I think it is work making the following point that 700k does very little, as on a straight line basis they are drawing down their contracted order book at @ 600k per month. It also is only a few percent more than the total annual cost of employing the CEO.
To materially change their outlook they need 2 or 3 large Phase II or Phase III contract wins and they sort of need them in the next 6 months. Another short term difficulty they need to overcome is the collapse of SVB bank in California, the small cap biotech industry on the west cost are a significant part of their customer base. It is possible, but maybe not highly probable that one of their new smaller clients will have been effected and will struggle to fund existing contracted work. The more likely knock on effect is going to be a general and continued funding drought for biotechs. This is going to slow how quickly they are able to fill the top of the funnel, the more preclinical and phase I work they have then the higher chances of a therapy making it to Phase II.
I still contend that radical change is needed here. The board and the C suite need to be replaced, IXICOs ambitions and in particular its sprawling R&D work need to be pared right back (for now). They need to get profitable with the work that they have on hand and have a high probability of winning and they need to divert time and treasure towards enhanced business development. |
Good to see first new contract win for a little while - after the small flurry of contract wins last summer. To my mind, it would be better for shareholders if the contract wins were in AD, which seems the most promising research area over the next few years. I think I am right in saying that the last contact win announced in AD was in Feb 2022. |
IXI have a huge increasing interest of its AI Products , is this when the company orders and sales pipeline grows quickly.
Maybe a Takeover on the cards as IXICO price levels are attractive at the current levels.
IXI future is very bright so get ready for dramatic price increases ahead.
Expect RNS soon |
@halfpenny, I guess we have different views of what constitutes record breaking ! In my view the only record they are likely to break in the near term, is a record low share price.
Management are obscenely overpaid, the board is stale and out of its depth, the companies accounting policies are aggressive and they are at best 2 to 3 years from a meaningful recovery in revenue, they admit that themselves. In getting there they will exhaust almost all of their cash pile.
My view, without something very significant in the near term this will trade in the teens and get bought out at or below the current shareprice. |
Ixico shares rise on double-digit revenue expectations for 2024 hence a record breaking year ahead and beyond..
IXI can beat previous sales with a focus on Sales and New A1 Products/Services which is in high demand.
The outlook and expectations are high and expect New Order demands to be high and beat market expectations.
The future for IXI is bright so get ready.. |
@halfpenny.... Can you explain what you mean by the phrase record breaking year ahead ? As I cannot see that in the key financial metrics, because both in terms of revenue and profit 2023 and 2024 will be significantly lower than FY 2022.
For what it is worth the house broker has them with and EBIT loss of 1.86 million this year (2023) and despite the 10% increase in revenue they have indicated for FY 2024 they are still showing an EBIT loss for FY 2024 of 1.69 million.
The board and management are the problem here not the business itself. The CEO and CFO are amongst the highest paid on AIM and in my view completely ineffective and the board is old and stale. Over the last 4 years they have too much focus on R&D and not enough on business development, this will take time to correct but it should be started now. |
IXI with large order flow so expect RNS soon. They have a record breaking year ahead and great growth as stated recently.
Future looking bright for IXI. |
Wow!! great results and now turning a corner as prospects and sales improve. IXI can now start heading towards previous highs.
They now have the AI Products and Services and strong interest in sales. Many companies are setting lower targets so they can beat market expectations with IXI next level of resistance 40p then once broken 60p plus more as orders start flowing in.
Future looking very bright with strong AI solutions which are in High Demand. |
Trading Update - So revenue for this year expected to be 7 million, and EBITDA loss of GBP 1.1 million and revenue for next year to be 10% higher. That would still be a loss for next year.
Of course if the C suite were not so outrageously paid, then would only be a small loss this year and decently paid next year.
A radical board and management change is required here. |
@Cliff, thanks. |
Presentation now back up on YouTube |
Maybe it was related to this, which was released during the day, yesterday. It is the Phase II contracts they are hoping to convert in to the much more substantial Phase III contracts, so it knocks out one of the contracts they could potentially convert.
8 December 2022
IXICO plc ("IXICO" or the "Company")
Contract update
IXICO plc (AIM: IXI), the precision analytics company delivering intelligent insights in neuroscience, announces that it has been notified by a client that the client has decided to discontinue a phase two trial that was previously announced by the Company. While this is expected to result in a reduction in management's previously anticipated revenues for 2023 of £0.1m and a total reduction in the Company's orderbook of £0.6 million, market guidance will not be impacted. |
That is very odd. There was no obvious material information disclosed on the call. Unless it is something mundane, like the video needed to be reedited, it would have to be that they mistakenly provided some incorrect information or the NOMAD objected to the upbeat tone of the presentation vs the subdued near term outlook. |
Nahh no luck. I see what you mean but I can't find any other version. |
Casholaa
This is the link from Investor meet Company tweet:
and YouTube: |
odd. do you have a url for the youtube vid??? |
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Hot Features
Premium
